Novo Nordisk A/S

Novo Nordisk A/S（NVO）股票分析

$39.220

+1.133 (+2.89%)收盤時

Loading chart…
最高
39.679
開盤
38.990
成交量加權均價
39.26
成交量
14.77M
市值
643.52B
最低
38.890
成交金額
580.07M
企業價值/稅息折舊攤銷前利潤（TTM）
1.68

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

www.novonordisk.com

AI 分析 of Novo Nordisk A/S (NVO)

持有

Novo Nordisk is currently a hold. The stock is trading at $38.64, which is below the analyst price target of $40 from Morgan Stanley, indicating limited upside. Additionally, the forward P/E ratio is 11.83, suggesting it may be undervalued, but the company faces significant competition from Eli Lilly, which could impact future growth.

分析師評級（1）

上檔空間 +39.39%
持有
0 買進
1 持有
0 賣出
目前: 39.22
最低
42.00
平均
54.67
最高
70.00

BMO Capital

2026-10-12

目標價

$40

Market Perform

Citi

2026-10-09

目標價

—

中性

Deutsche Bank

2026-09-22

目標價

—

賣出

Morgan Stanley

2026-09-11

目標價

$40

減持

HSBC

2026-09-10

目標價

—

持有
查看全部評級

估值指標

Novo Nordisk A/S（NVO）目前預期本益比為 11.83，5 年平均預期本益比為 25.71。

預期本益比

低估
5 年均值 P/E
25.71
目前P/E
11.83
高估
34.51
低估
16.92

預期 EV/EBITDA

低估
5 年均值 EV/EBITDA
17.14
目前EV/EBITDA
1.68
高估
25.24
低估
9.04

預期股價營收比

低估
5 年均值 P/S
8.24
目前P/S
0.55
高估
12.27
低估
4.21

Alphio AI 對 NVO 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重（25 / 50 / 25），不構成保證。

樂

樂觀

樂觀 · 25%NVO

$87.35

情境價格

基

基準

基準 · 50%NVO

$84.65

情境價格

悲

悲觀

悲觀 · 25%NVO

$73.30

情境價格

持有 NVO 的大戶

F

Folketrygdfondet

+ 持有NVO

+16.94%

3個月報酬率

C

Compound Global Advisors, LLC

+ 持有NVO

+11.01%

3個月報酬率

U

United Capital Financial Advisors

+ 持有NVO

+7.72%

3個月報酬率

C

Carmignac Gestion SA

+ 持有NVO

+7.60%

3個月報酬率

L

Loomis, Sayles & Company L.P.

+ 持有NVO

+7.38%

3個月報酬率

I

Ibercaja Gestion SGIIC SA

+ 持有NVO

+6.45%

3個月報酬率

事件時間軸

2026-10-15 (ET)

11:00:00

Novo Nordisk Shares Rise 2.9% to $39.23

05:30:00

Evotec Appoints Joanna Holbrook as Chief Scientific Officer

2026-10-02 (ET)

10:30:00

Novo Nordisk Shares Up 0.39% to $37.55

2026-10-01 (ET)

16:00:00

Novo Nordisk Shares Slightly Down, Options Activity Moderate

2026-09-30 (ET)

17:00:00

Novo Nordisk Shares Slightly Down, Options Activity Moderate

查看更多事件

資訊

查看更多資訊

NVO 常見問題 —— 由 Alphio AI 解答

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Novo Nordisk is currently a hold. The stock is trading at $38.64, which is below the analyst price target of $40 from Morgan Stanley, indicating limited upside. Additionally, the forward P/E ratio is 11.83, suggesting it may be undervalued, but the company faces significant competition from Eli Lilly, which could impact future growth.

1 analysts cover NVO: 0 rate it Buy, 1 Hold and 0 Sell. The average price target is 54.67.

社群

更多 ↗
分享你對 NVO 的看法
發布
lunarviper昨天

🚨 $VKTX just took a major step toward bringing its obesity pill to market! Viking Therapeutics has initiated two Phase 3 trials of oral VK2735, targeting patients with obesity both with and without Type 2 diabetes. 📊 Phase 2 results showed up to 12.2% mean weight loss in just 13 weeks, versus 1.3% with placebo. 🔥 The bigger picture? > Injectable VK2735 is already in Phase 3, with enrollment completed in both studies. > Maintenance data showed patients retained 85–90% of prior weight loss with less frequent injections. > Oral maintenance research and VK3019 add further potential to the pipeline. Competition from $LLY and $NVO is heating up, but Viking is expanding its options across oral, injectable and maintenance treatments.

展開
$ VKTX$ LLY$ NVO
00
ScalpWalker2026/9/30

$NVO $LLY Novo says Ozempic shows lower risk of cardiovascular events compared to Lilly's Mounjaro - Reuters

展開
$ NVO$ LLY
00
0xGreedycitadel2026/9/23

$NVO has 30+ AI strategic partnerships and 600+ AI & digital professionals working alongside its scientists on drug discovery. Novo chief scientific officer: "We have identified not only new targets but also drugs with the help of AI." Ambition to launch >5 multi-blockbusters by 2030 & deliver combined pipeline sales of >150B DKK ($22.86B) in 2035.

展開
$ NVO
00
註冊或登入後參與討論

本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易